Information Provided By:
Fly News Breaks for July 11, 2016
HZNP
Jul 11, 2016 | 09:02 EDT
Morgan Stanley upgraded Horizon Pharma to Equal Weight and maintained its $24 price target citing potential near-term newsflow from a potential PBM contract for 2017, top-line results for Actimmune in Friedreich's ataxia of FA at the end of the year, and increasing Krystexxa sales expectations.
News For HZNP From the Last 2 Days
There are no results for your query HZNP